Invented by Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen, IBC Pharmaceuticals Inc

The market for combination therapy to induce immune response against disease is rapidly growing as researchers and pharmaceutical companies recognize the potential of this approach in treating a wide range of diseases. Combination therapy involves the use of multiple drugs or treatment modalities to enhance the immune system’s ability to fight off diseases. The immune system plays a crucial role in protecting the body against infections and diseases. However, in some cases, the immune response may be weak or ineffective, leading to the progression of diseases such as cancer, autoimmune disorders, and chronic infections. This is where combination therapy comes into play. Combination therapy works by targeting multiple pathways or mechanisms involved in the immune response. By using different drugs or treatment modalities, researchers can enhance the immune system’s ability to recognize and destroy diseased cells or pathogens. This approach has shown promising results in preclinical and clinical studies, leading to increased interest and investment in this field. One example of combination therapy is the use of immune checkpoint inhibitors in combination with other immunotherapies. Immune checkpoint inhibitors are drugs that block proteins on immune cells, allowing them to recognize and attack cancer cells more effectively. When combined with other immunotherapies, such as cancer vaccines or adoptive cell therapies, the immune response against cancer can be significantly enhanced. Another example is the combination of targeted therapies with immunotherapies. Targeted therapies are drugs that specifically target cancer cells based on their genetic or molecular characteristics. When combined with immunotherapies, such as immune checkpoint inhibitors or cytokines, targeted therapies can help to stimulate the immune system’s response against cancer cells, leading to improved outcomes for patients. The market for combination therapy in inducing immune response against disease is expected to grow significantly in the coming years. According to a report by Grand View Research, the global cancer immunotherapy market, which includes combination therapies, is projected to reach $126.9 billion by 2026, growing at a compound annual growth rate (CAGR) of 9.6%. The increasing prevalence of cancer and other chronic diseases, coupled with the growing understanding of the immune system and its role in disease progression, are driving the demand for combination therapy. Additionally, advancements in technology, such as next-generation sequencing and high-throughput screening, are enabling researchers to identify new drug targets and develop more effective combination therapies. However, there are challenges that need to be addressed in the development and commercialization of combination therapies. These include the identification of optimal drug combinations, understanding the mechanisms of action and potential side effects, and navigating the regulatory landscape for combination therapies. In conclusion, the market for combination therapy to induce immune response against disease is expanding rapidly, driven by the need for more effective treatments for cancer, autoimmune disorders, and chronic infections. The potential of combination therapy to enhance the immune system’s ability to fight off diseases is attracting significant investment and research efforts. As our understanding of the immune system and disease mechanisms continues to grow, we can expect to see more innovative combination therapies entering the market, offering new hope for patients and improving outcomes in the fight against diseases.

The IBC Pharmaceuticals Inc invention works as follows

The present invention relates to compositions and methods for using bispecific antibodies that contain at least one site of binding for Trop-2 (EGP-1), and at least another site of binding for CD3. Bispecific antibodies can be used to induce an immune response in a tumor expressing Trop-2, such as a cancer of the esophagus or pancreas. They may also be administered with other therapeutic agents, including interferons (preferably interferon-? Methods may include administering the bispecific antibodies alone or in combination with other therapeutic agents, such as interferons, antibody-drug conjugates or interferon-? The bispecific antibody can be administered alone or with other therapeutic agents such as interferons (preferably interferon-? The bispecific antibodies can target effector T-cells, NK cells or monocytes and neutrophils in order to induce leukocyte mediated cytotoxicity against Trop-2+ cancerous cells. “The cytotoxic response is enhanced when interferon and checkpoint inhibitor antibodies are administered together with ADCs or ADCs.

Background for Combination therapy to induce immune response against disease


Leukocyte-Redirecting Bispecific Immunocomplexes


Example 3. Interferon-? “Leukocyte Redirecting Antibodies Enhance the Cytotoxic Action of Interferon-?

Example 4. “Example 4. Combination Therapy with Leukocyte-Redirecting Bispecific Antibodies

Example 5. “Example 5. Combination Therapy with Bispecific Antibodies that Redirect T-Cells in Human Gastric Cancer

Example 6. “Example 6.

Example 7. “Example 7.

Example 8. “Example 8.

Example 9. ADC therapy with IMMU 132 for Metastatic Solid Cancers

Example 10. IMMU-130 is a SN-38 ADC targeting CEACAM5 that is therapeutically active in metastatic colorectal cancer (mCRC).

Example 11. “Example 11. Antitumor Activity of Checkpoint Inhibitor Antibody Alone or Combined with T-Cell Redirecting bsAb, IFN-?

Example 13. Combination Therapy using ADC (IMMU-131) and T-Cell-Redirecting bsAbs (MT100) for Advanced Colonic Cancer

Example 14. Combination Therapy using ADC (IMMU-135) and T-Cell Redirecting bsAbs ((E1)-3s), Interferon-? To Treat Metastatic Gastric Cancer Patients

Example 16. “Example 16.

Example 17. How to make and use a DNL? Construct Comprising two Different Antibody Moieties, and a Cytokine

Example 18. Use of NK-Targeted Leukocyte-Redirecting bsAbs

Click here to view the patent on Google Patents.